Athersys - 48 Year Dividend History | ATHX

Historical dividend payout and yield for Athersys (ATHX) since 1971. The current TTM dividend payout for Athersys (ATHX) as of June 24, 2019 is $0.00. The current dividend yield for Athersys as of June 24, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.264B $0.024B
Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $114.125B 12.90
Gilead Sciences (GILD) United States $88.452B 10.74
Bio-Techne Corp (TECH) United States $7.965B 54.34